Toggle Health Problems and D

COVID-19 Long haul - excellent graph - systematic review May 26, 2021

Assessment of the Frequency and Variety of Persistent Symptoms Among Patients With COVID-19 A Systematic Review

JAMA Netwoh< Open. 2021;4(5):e2111417. doi:10.1001/jamanetworkopen.2021.11417
Tahmina Nasserie, MPH; Michael Hittle, BS; Steven N. Goodman, MD, MHS, PhD
The horizontal bar extends from the first to the third quartile, the interquartile range (IQR).
The whiskers extend from the upper and lower quartiles to the largest value within 1.5 IQRs of that quartile.
The width of the box represents the IQR.
The vertical bar represents the median value for the outcome.
The circles represent point estimates from each study.
  Circles beyond the whiskers are considered outliers.


Vitamin D titles containing "long-haul"

Items found: 17
Title Modified
COVID-19 long haul - meta-analysis, Vitamin D, etc. 23 Dec, 2021
Some COVID-19 infection become COVID Long-Haul - Nov 2020 15 Dec, 2021
Epstein-Barr Virus may cause Long-Haul, CFS, and MS (Vitamin D should help) 11 Dec, 2021
Epstein-Barr virus appears to cause Long-Haul and Chronic fatiure Syndrome (Vitamin D might help) 11 Dec, 2021
Long-haul after breakthrough COVID – Nov 2021 11 Dec, 2021
Long-Haul COVID is a problem even if vaccinated (Veterans)– Nov 2021 24 Nov, 2021
Long-haul, VAERS, Ivermectin, vaccines, etc. Drs. Seheult, Patrick: Video with table of contents - Sept 17, 2021 21 Sep, 2021
Your Brain on Covid-19 Long-Haul, Dr. Galland video and transcript - Aug 1, 2021 07 Aug, 2021
Long-haul COVID-19 blood tests at Mayo include vitamin D (but no results published) – July 2021 20 Jul, 2021
Most people with Long-Haul COVID-19 have low Vitamin D – July 2021 15 Jul, 2021
‘Long haul’ COVID rehab worse than cancer rehab, CDC – July 2021 13 Jul, 2021
Long-Haul COVID-19 occurred to 1 in 20 who had been asymptomatic (a study of 2 million with COVID-19) – June 2021 15 Jun, 2021
COVID-19 Long haul - excellent graph - systematic review May 26, 2021 26 May, 2021
Long-haul COVID-19 - another hint that Vitamin D should help - Dec 2020 16 Apr, 2021
Chronic Fatigue Syndrome and long-haul COVID-19 02 Apr, 2021
Probably fewer long-haul COVID-19 problems when rejuvenated immune system (Vitamin D, etc.)– Dec 2020 21 Feb, 2021
Long-haul fatigue, etc. common after viral infections (SARS1,2, MERS, Swine, 1918,...) 21 Feb, 2021

 Download the PDF from VitaminDWiki

Key Points

  • Question What are the frequency and variety of persistent symptoms after COVID-19 infection?
  • Findings In this systematic review of 45 studies including 9751 participants with COVID-19, the median proportion of individuals who experienced at least 1 persistent symptom was 73%; symptoms occurring most frequently included shortness of breath or dyspnea, fatigue or exhaustion, and sleep disorders or insomnia. However, the studies were highly heterogeneous and needed longer follow-up and more standardized designs.
  • Meaning This systematic review found that COVID-19 symptoms commonly persisted beyond the acute phase of infection, with implications for health- associated functioning and quality of life; however, methodological improvements are needed to reliably quantify these risks.

IMPORTANCE Infection with COVID-19 has been associated with long-term symptoms, but the frequency, variety, and severity of these complications are not well understood. Many published commentaries have proposed plans for pandemic control that are primarily based on mortality rates among older individuals without considering long-term morbidity among individuals of all ages. Reliable estimates of such morbidity are important for patient care, prognosis, and development of public health policy.

OBJECTIVE To conduct a systematic review of studies examining the frequency and variety of persistent symptoms after COVID-19 infection.

EVIDENCE REVIEW A search of PubMed and Web ofScience was conducted to identify studies published from January 1, 2020, to March 11,2021, that examined persistent symptoms after COVID-19 infection. Persistent symptoms were defined as those persisting for at least 60 days after diagnosis, symptom onset, or hospitalization or at least 30 days after recovery from the acute illness or hospital discharge. Search terms included COVID-19, SARS-CoV-2, coronavirus, 2019-nCoV, longterm, after recovery, long-haul, persistent, outcome, symptom, follow-up, and longitudinal. All English-language articles that presented primary data from cohort studies that reported the prevalence of persistent symptoms among individuals with SARS-CoV-2 infection and that had clearly defined and sufficient follow-up were included. Case reports, case series, and studies that described symptoms only at the time of infection and/or hospitalization were excluded. A structured framework was applied to appraise study

FINDINGS A total of 1974 records were identified; of those, 1247 article titles and abstracts were screened. After removal of duplicates and exclusions, 92 full-text articles were assessed for eligibility; 47 studies were deemed eligible, and 45 studies reporting 84 clinical signs or symptoms were included inthe systematic review. Of 9751 total participants, 5266 (54.0%) were male; 30 of 45 studies reported mean or median ages younger than 60 years. Among 16 studies, most of which comprised participants who were previously hospitalized, the median proportion of individuals experiencing at least 1 persistent symptom was 72.5% (interquartile range IQR, 55.0%-80.0%). Individual symptoms occurring most frequently included shortness of breath or dyspnea (26 studies; median frequency, 36.0%; IQR, 27.6%-50.0%), fatigue or exhaustion (25 studies; median frequency, 40.0%; IQR, 31.0%-57.0%), and sleep disorders or insomnia (8 studies; median 29.4%, IQR, 24.4%-33.0%). There were wide variations in the design and quality of the studies, which had implications for interpretation and often limited direct comparability and combinability. Major design differences included patient populations, definitions of time zero (ie, the beginning of the follow-up interval), follow-up lengths, and outcome definitions, including definitions of illness severity.

CONCLUSIONS AND RELEVANCE This systematic review found that COVID-19 symptoms commonly persisted beyond the acute phase of infection, with implications for health-associated functioning and quality of life. Current studies of symptom persistence are highly heterogeneous, and future studies need longer follow-up, improved quality, and more standardized designs to reliably quantify risks.

Attached files

ID Name Comment Uploaded Size Downloads
15649 LH review 2.jpg admin 26 May, 2021 20:04 31.03 Kb 150
15648 LH review 1.jpg admin 26 May, 2021 20:04 48.17 Kb 181
15647 COVID-19 long-haul review_compressed.pdf PDF 2021 admin 26 May, 2021 20:04 194.21 Kb 118
See any problem with this page? Report it (WORKS NOV 2021)